Related Experiment Videos

Efficacy of methylprednisolone in children with severe community acquired pneumonia

Bela Nagy1, Imre Gaspar, Agnes Papp

  • 1Department of Pediatrics, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary. bnagy@dote.hu

Pediatric Pulmonology
|May 17, 2012
PubMed

Insights

Adjuvant methylprednisolone therapy significantly improved outcomes for children with severe community-acquired pneumonia (CAP). This 5-day treatment reduced fever, white blood cell counts, C-reactive protein levels, and hospital stays, while lowering complication rates.

Area of Science:

  • Pediatric critical care medicine
  • Infectious diseases
  • Clinical pharmacology

Background:

  • Adjuvant corticosteroid use in pediatric community-acquired pneumonia (CAP) lacks extensive data.
  • Existing research on corticosteroids for adult CAP shows controversial clinical value.

Purpose of the Study:

  • To investigate the efficacy of a 5-day adjuvant methylprednisolone therapy combined with imipenem in children with severe CAP.
  • To compare outcomes between children receiving methylprednisolone plus imipenem versus imipenem plus placebo.

Main Methods:

  • A comparative study involving 29 children with severe CAP treated with methylprednisolone and imipenem.
  • A control group of 30 children with severe CAP received imipenem and placebo.
  • Primary endpoints included fever duration, white blood cell (WBC) counts, and high-sensitivity C-reactive protein (hsCRP) levels.
  • Secondary endpoints assessed length of hospital stay and incidence of severe complications.

Main Results:

  • Methylprednisolone significantly reduced fever duration by 2.5 days.
  • The treatment group showed significantly lower WBC counts (P=0.014) and a 48.7% decrease in hsCRP levels.
  • Hospital stay was reduced by 5.2 days in the methylprednisolone group.
  • Complication rates and need for invasive interventions were substantially lower compared to the placebo group.

Conclusions:

  • A 5-day course of methylprednisolone combined with imipenem is effective for treating severe pediatric CAP.
  • Further large-scale trials are warranted to fully elucidate the benefits of corticosteroids in pediatric CAP management.
Abstract

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: